Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported fourth-quarter 2025 results showing continued commercial uptake of its lead product Rezdiffra (resmetirom), with…
Genmab A/S (Nasdaq: GMAB) released its full-year 2025 financial results, demonstrating the company's improved operational execution. Total revenue reached $3.72…